Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Imron T. Aly is a trial lawyer who serves as lead counsel for clients on dozens of matters, and has first-chaired more than 10 trials. Imron is co-leader of Schiff Hardin’s Intellectual Property Group and co-chair of the firm's Hatch-Waxman and Biosimilars patent litigation team. His practice is focused on patent infringement litigation. He has litigated and tried patent infringement and other IP matters related to pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods, and financial trading systems.
Clients and leading industry publications describe Imron as a prepared courtroom advocate whose “tenacity sets him apart,” who “stands out for his pure advocacy skills,” and “is an untiring advocate for his clients’ cause.” In the 2020 Chambers USA guide, clients commended his litigation capabilities, saying, “He is very technically sophisticated, extraordinarily persuasive and an extremely effective trial counsel.”
Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.
Schiff Hardin LLP is pleased to announce that the firm’s Intellectual Property Practice Group has received the Impact Case of the Year award in 2020 by LMG Life Sciences for our ground-breaking patent-infringement victory in Fresenius Kabi v. Hospira.
Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.
The Center for Biosimilars
Schiff Hardin is pleased to announce that three Intellectual Property Practice Group attorneys have been recognized as IP Stars in Illinois for 2020 by Managing Intellectual Property.
Schiff Hardin is pleased to announce that five practice areas have been ranked in Chambers USA 2020 guide, up one from 2019 with a first-time ranking for Energy & Natural Resources.
Schiff Hardin LLP
Schiff Hardin LLP is pleased to announce that 88 attorneys have been named to the 2020 Leading Lawyers list.
We are pleased to announce that 32 Schiff Hardin attorneys have been recognized on the 2020 Illinois Super Lawyers and Rising Stars lists.
Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.
LMG Life Sciences
Managing Intellectual Property
Chambers & Partners
Law Bulletin’s Illinois Leading Lawyers Network
Legal Media Group
IAM Patent 1000
Crain’s Chicago Business
Law Bulletin's Illinois Leading Lawyers Network
BTI Power Ranking
Globe Business Media Group's The World’s Leading Patent Practitioners (2014, 2015)
Chambers USA: America’s Leading Lawyers for Business (2014)
Euromoney's Benchmark Litigation (2013, 2014)
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading
Aly and Patel are Strategic, Must-Have Advisers Who Bring Generic Drugs to Market Copy: Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace.
Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation.